Adjei AA - Search Results

1

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.

Ngamphaiboon N, Dy GK, Ma WW, Zhao Y, Reungwetwattana T, DePaolo D, Ding Y, Brady W, Fetterly G, Adjei AA. Ngamphaiboon N, et al. Among authors: adjei aa. Invest New Drugs. 2015 Feb;33(1):225-32. doi: 10.1007/s10637-014-0174-6. Epub 2014 Nov 5. Invest New Drugs. 2015. PMID: 25371323 Clinical Trial.

2

Novel pharmacological agents in clinical development for solid tumours.

Dy GK, Haluska P, Adjei AA. Dy GK, et al. Among authors: adjei aa. Expert Opin Investig Drugs. 2001 Dec;10(12):2059-88. doi: 10.1517/13543784.10.12.2059. Expert Opin Investig Drugs. 2001. PMID: 11772306 Review.

3

Novel targets for lung cancer therapy: part I.

Dy GK, Adjei AA. Dy GK, et al. Among authors: adjei aa. J Clin Oncol. 2002 Jun 15;20(12):2881-94. doi: 10.1200/JCO.2002.11.145. J Clin Oncol. 2002. PMID: 12065566 Review.

4

Novel targets for lung cancer therapy: part II.

Dy GK, Adjei AA. Dy GK, et al. Among authors: adjei aa. J Clin Oncol. 2002 Jul 1;20(13):3016-28. doi: 10.1200/JCO.2002.02.112. J Clin Oncol. 2002. PMID: 12089232 Review.

5

Farnesyl transferase inhibitors as anticancer agents.

Haluska P, Dy GK, Adjei AA. Haluska P, et al. Among authors: adjei aa. Eur J Cancer. 2002 Sep;38(13):1685-700. doi: 10.1016/s0959-8049(02)00166-1. Eur J Cancer. 2002. PMID: 12175684 Review.

6

A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.

Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. Adjei AA, et al. Invest New Drugs. 2002 Aug;20(3):297-304. doi: 10.1023/a:1016237426846. Invest New Drugs. 2002. PMID: 12201492 Clinical Trial.

7

Farnesyltransferase inhibitors in breast cancer therapy.

Dy GK, Adjei AA. Dy GK, et al. Among authors: adjei aa. Cancer Invest. 2002;20 Suppl 2:30-7. doi: 10.1081/cnv-120014884. Cancer Invest. 2002. PMID: 12442347 Review.

8

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. Adjei AA, et al. Clin Cancer Res. 2003 Jan;9(1):115-23. Clin Cancer Res. 2003. PMID: 12538459 Clinical Trial.

9

A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.

Dees EC, Rowinsky EK, Noe DA, O'Reilly S, Adjei AA, Elza-Brown K, Donehower RC. Dees EC, et al. Among authors: adjei aa. Invest New Drugs. 2003 Feb;21(1):75-84. doi: 10.1023/a:1022924511602. Invest New Drugs. 2003. PMID: 12795532 Clinical Trial.

10

The role of farnesyltransferase inhibitors in lung cancer therapy.

Dy GK, Adjei AA. Dy GK, et al. Among authors: adjei aa. Clin Lung Cancer. 2002 Jul;4(1):57-62. doi: 10.3816/clc.2002.n.017. Clin Lung Cancer. 2002. PMID: 14653878

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

457 results

Search Page